EHA 2022 | Current standard of care in BPDCN
In this video, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the current standard of care (SOC) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), drawing focus on the use of tagraxofusp, as well as the use of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)-based regimens and the importance of transplantation. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis
